Analysts Anticipate Adamas Pharmaceuticals Inc (ADMS) Will Announce Earnings of -$1.13 Per Share

Wall Street brokerages expect Adamas Pharmaceuticals Inc (NASDAQ:ADMS) to report earnings per share (EPS) of ($1.13) for the current quarter, according to Zacks. Five analysts have issued estimates for Adamas Pharmaceuticals’ earnings, with estimates ranging from ($1.31) to ($1.07). Adamas Pharmaceuticals reported earnings per share of ($1.35) during the same quarter last year, which suggests a positive year-over-year growth rate of 16.3%. The company is expected to announce its next earnings report after the market closes on Thursday, May 9th.

On average, analysts expect that Adamas Pharmaceuticals will report full year earnings of ($4.14) per share for the current fiscal year, with EPS estimates ranging from ($4.56) to ($3.65). For the next financial year, analysts expect that the company will post earnings of ($2.23) per share, with EPS estimates ranging from ($2.65) to ($1.50). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Adamas Pharmaceuticals.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Monday, March 4th. The specialty pharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.36) by $0.30. The business had revenue of $13.32 million during the quarter, compared to analyst estimates of $13.30 million. Adamas Pharmaceuticals had a negative return on equity of 101.46% and a negative net margin of 384.77%.

ADMS has been the subject of several research reports. Mizuho reiterated a “hold” rating and set a $11.00 price target on shares of Adamas Pharmaceuticals in a report on Friday, January 11th. Zacks Investment Research lowered Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, January 14th. HC Wainwright set a $40.00 price objective on Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, January 14th. ValuEngine downgraded Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. Finally, BidaskClub raised Adamas Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, February 15th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $22.29.

In related news, CEO Gregory T. Went sold 6,319 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $7.99, for a total value of $50,488.81. Following the transaction, the chief executive officer now directly owns 176,291 shares of the company’s stock, valued at approximately $1,408,565.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 8,361 shares of company stock worth $66,816 over the last three months. 24.90% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of ADMS. BlackRock Inc. raised its stake in shares of Adamas Pharmaceuticals by 2.4% in the 3rd quarter. BlackRock Inc. now owns 1,889,914 shares of the specialty pharmaceutical company’s stock valued at $37,836,000 after acquiring an additional 43,818 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Adamas Pharmaceuticals in the 3rd quarter valued at approximately $2,209,000. Jane Street Group LLC bought a new position in shares of Adamas Pharmaceuticals in the 3rd quarter valued at approximately $324,000. Pacer Advisors Inc. bought a new position in shares of Adamas Pharmaceuticals in the 3rd quarter valued at approximately $104,000. Finally, MetLife Investment Advisors LLC raised its stake in shares of Adamas Pharmaceuticals by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 16,709 shares of the specialty pharmaceutical company’s stock valued at $335,000 after acquiring an additional 5,940 shares in the last quarter. 88.51% of the stock is currently owned by institutional investors and hedge funds.

Shares of Adamas Pharmaceuticals stock traded down $0.04 during trading on Thursday, hitting $5.93. 449,310 shares of the stock traded hands, compared to its average volume of 511,337. The firm has a market cap of $163.19 million, a price-to-earnings ratio of -1.22 and a beta of 1.35. The company has a debt-to-equity ratio of 1.31, a current ratio of 9.41 and a quick ratio of 9.20. Adamas Pharmaceuticals has a twelve month low of $5.85 and a twelve month high of $32.90.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

See Also: What is the Fibonacci sequence?

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.